SCHEMBL3760152

SCHEMBL3760152

C#CCN(C)S(=O)(=O)c1ccc(Cn2nc(C(=O)Nc3ccc(C(N)=O)cc3)c3ccccc32)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 9/20 0.44
HDAC3 O15379 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC2 Q92769 1/20 0.43
HDAC10 Q969S8 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
NCOR2 Q9Y618 1/20 0.43
KDM4E B2RXH2 2/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
CNR1 P21554 1/20 0.42
MCL1 Q07820 1/20 0.41
KLK7 P49862 1/20 0.40
CYP2D6 P10635 2/20 0.40
ALDH1A1 P00352 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
ALOX15 P16050 1/20 0.40
IDH1 O75874 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3762387 0.89 KDM4E (0.42) PTGER4HDAC3HDAC1HDAC2HDAC10
SCHEMBL3754165 0.86 ALDH1A1 (0.42) PTGER4KDM4EMEN1KMT2AMCL1
SCHEMBL3430845 0.84 KMT2A (0.45) KDM4EMEN1KMT2AALDH1A1ALOX15
SCHEMBL3755332 0.78 KDM4E (0.54) PTGER4HDAC3HDAC1HDAC2HDAC10
SCHEMBL3430447 0.77 KMT2A (0.54) MEN1KMT2ACYP2D6ALDH1A1CYP1A2
SCHEMBL3428395 0.75 PTGER4 (0.54) PTGER4KDM4EMEN1KMT2ACNR1
SCHEMBL4252020 0.75 CNR1 (0.48) PTGER4HDAC3HDAC1HDAC2HDAC10
SCHEMBL3430198 0.74 KDM4E (0.51) PTGER4HDAC3HDAC1HDAC2HDAC10
SCHEMBL3428006 0.74 PTGER4 (0.57) PTGER4KDM4EMEN1KMT2ACNR1
SCHEMBL3428570 0.74 KDM4E (0.51) PTGER4HDAC3HDAC1HDAC2HDAC10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US claimed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US disclosed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US disclosed
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED 2010-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305120-A1 COMPOUNDS FOR TREATING MUSCULAR DYSTROPHY CPT1B, SMN1; SMN2, GYS1 PTGER4 3500/4885HDAC3 128/4885HDAC1 61/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.